MondayNightIBD | Small Bowel Adenocarcinoma | May 1, 2023 | Daniel Stein, MD
Pre-assessment

Before you participate in this activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

Question Title

* 1. Where are you in your career?

IBD Specialist

General GI

Fellow/Trainee

APP

PharmD

Other (please specify)

Question Title

* 2. Which one is true regarding small bowel carcinoma in patients with Crohn’s disease?

10% lifetime risk of developing SB carcinoma

Occurs early after the diagnosis of Crohn’s disease

More common in patients with ileocolonic disease than in isolated small bowel disease

More than 50% of SB carcinoma are found incidentally on resected surgical specimen

Question Title

* 3. 45 year old male with isolated ileal Crohn’s diagnosed 10 years ago and in remission on adalimumab for the last 5 years presents for follow-up. He heard about the increase in risk of small bowel cancer and asks what he can do about it. What information do you share with him?

Overall risk is very low, there are no surveillance recommendations

Needs exam of TI + biopsies every 1-2 years

Needs MR enterography every 1-2 years

Needs intestinal ultrasound every 1-2 years

Question Title

* 4. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity)

First & Last Name

State/Province

ZIP/Postal Code

Country

Email Address

MondayNightIBD | Small Bowel Adenocarcinoma | May 1, 2023 | Daniel Stein, MD **Pre-assessment**

Question Title

* 1. Where are you in your career?

Question Title

* 2. Which one is true regarding small bowel carcinoma in patients with Crohn’s disease?

Question Title

* 3. 45 year old male with isolated ileal Crohn’s diagnosed 10 years ago and in remission on adalimumab for the last 5 years presents for follow-up. He heard about the increase in risk of small bowel cancer and asks what he can do about it. What information do you share with him?

Question Title

* 4. Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity)

MondayNightIBD | Small Bowel Adenocarcinoma | May 1, 2023 | Daniel Stein, MD
Pre-assessment